PH12019500853A1 - Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins - Google Patents
Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteinsInfo
- Publication number
- PH12019500853A1 PH12019500853A1 PH12019500853A PH12019500853A PH12019500853A1 PH 12019500853 A1 PH12019500853 A1 PH 12019500853A1 PH 12019500853 A PH12019500853 A PH 12019500853A PH 12019500853 A PH12019500853 A PH 12019500853A PH 12019500853 A1 PH12019500853 A1 PH 12019500853A1
- Authority
- PH
- Philippines
- Prior art keywords
- present disclosure
- ligand trap
- methods
- actriib ligand
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 4
- 101100437153 Rattus norvegicus Acvr2b gene Proteins 0.000 title abstract 3
- 239000003446 ligand Substances 0.000 title abstract 3
- 208000020084 Bone disease Diseases 0.000 title abstract 2
- 206010028289 Muscle atrophy Diseases 0.000 title abstract 2
- 201000000585 muscular atrophy Diseases 0.000 title abstract 2
- 108090000623 proteins and genes Proteins 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 3
- 201000011529 cardiovascular cancer Diseases 0.000 abstract 2
- 208000020832 chronic kidney disease Diseases 0.000 abstract 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000032683 aging Effects 0.000 abstract 1
- 208000007502 anemia Diseases 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 206010003246 arthritis Diseases 0.000 abstract 1
- 230000001363 autoimmune Effects 0.000 abstract 1
- 230000010261 cell growth Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 208000019423 liver disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000033667 organ regeneration Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- 230000017423 tissue regeneration Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410595P | 2016-10-20 | 2016-10-20 | |
| PCT/US2017/057351 WO2018075747A1 (en) | 2016-10-20 | 2017-10-19 | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PH12019500853A1 true PH12019500853A1 (en) | 2019-12-02 |
Family
ID=62019496
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PH12019500853A PH12019500853A1 (en) | 2016-10-20 | 2019-04-17 | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins |
Country Status (22)
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| MA41919A (fr) | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| JP6810702B2 (ja) | 2015-04-06 | 2021-01-06 | アクセルロン ファーマ インコーポレイテッド | シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用 |
| KR102761094B1 (ko) | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JP7219705B2 (ja) | 2016-10-05 | 2023-02-08 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ４：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| US11013785B2 (en) | 2016-11-10 | 2021-05-25 | Keros Therapeutics, Inc. | Activin receptor type IIA variants and methods of use thereof |
| KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
| CN120535607A (zh) | 2018-01-12 | 2025-08-26 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
| AU2019266314B2 (en) | 2018-05-09 | 2025-05-15 | Keros Therapeutics, Inc. | Activin receptor type iia variants and methods of use thereof |
| KR20220148189A (ko) * | 2020-02-03 | 2022-11-04 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| EP4121090A4 (en) * | 2020-03-20 | 2024-09-04 | Keros Therapeutics, Inc. | Methods of using activin receptor type iia variants |
| EP4121088A4 (en) * | 2020-03-20 | 2024-07-03 | Keros Therapeutics, Inc. | Methods of using activin receptor type iib variants |
| EP4121078A4 (en) * | 2020-03-20 | 2024-08-14 | Keros Therapeutics, Inc. | ACTIVIN RECEPTOR TYPE II CHIMERAS AND METHODS OF USE THEREOF |
| BR112022020628A2 (pt) * | 2020-04-13 | 2022-11-29 | Celgene Corp | Métodos para tratamento de anemia usando uma armadilha de ligante de actriib e fedratinibe |
| US20240181007A1 (en) * | 2021-01-08 | 2024-06-06 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
| EP4653010A1 (en) * | 2024-05-14 | 2025-11-26 | 35Pharma Inc. | Activin receptor type iib traps for use in improving body composition |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| JP2877509B2 (ja) | 1989-05-19 | 1999-03-31 | アムジエン・インコーポレーテツド | メタロプロテイナーゼ阻害剤 |
| US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
| US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
| JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
| CN1330664C (zh) | 2001-03-07 | 2007-08-08 | 默克专利有限公司 | 用于含杂合同种型抗体部分的蛋白质的表达技术 |
| AU2012204098B2 (en) | 2001-04-24 | 2014-05-15 | The Johns Hopkins University | Use of follistatin to increase muscle mass |
| US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
| JP5110877B2 (ja) | 2003-06-02 | 2012-12-26 | ワイス・エルエルシー | 神経筋障害を処置するための、コルチコステロイドと組み合わせたミオスタチン（ｇｄｆ８）インヒビターの使用 |
| EP1682584B1 (en) | 2003-11-13 | 2013-04-17 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprising an immunoglobulin fc region as a carrier |
| EP1771470B1 (en) * | 2004-07-23 | 2013-06-26 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
| AU2015200950B2 (en) | 2004-07-23 | 2017-04-27 | Acceleron Pharma Inc. | ActRII receptor polypeptides, methods and compositions |
| EP1778275A2 (en) | 2004-08-12 | 2007-05-02 | Wyeth | Combination therapy for diabetes, obesity, and cardiovascular diseases using gdf-8 inhibitors |
| US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| US9844528B2 (en) | 2006-08-24 | 2017-12-19 | University Of Tennessee Research Foundation | SARMs and method of use thereof |
| US20100028332A1 (en) | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
| EP2468290B1 (en) | 2006-12-18 | 2015-04-01 | Acceleron Pharma, Inc. | Activin-ActRII Antagonists for use in treating anemia |
| TWI782836B (zh) | 2007-02-02 | 2022-11-01 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
| US7947646B2 (en) * | 2007-03-06 | 2011-05-24 | Amgen Inc. | Variant activin receptor polypeptides |
| WO2013106175A1 (en) | 2011-12-19 | 2013-07-18 | Amgen Inc. | Variant activin receptor polypeptides, alone or in combination with chemotherapy, and uses thereof |
| US8501678B2 (en) * | 2007-03-06 | 2013-08-06 | Atara Biotherapeutics, Inc. | Variant activin receptor polypeptides and uses thereof |
| WO2009038745A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100015144A1 (en) | 2008-06-26 | 2010-01-21 | Acceleron Pharma Inc. | Methods for dosing an activin-actriia antagonist and monitoring of treated patients |
| JP5773868B2 (ja) | 2008-06-26 | 2015-09-02 | アクセルロン ファーマ， インコーポレイテッド | アクチビン−ＡｃｔＲＩＩａのアンタゴニストおよび赤血球レベルを高めるためのその使用 |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| US8058229B2 (en) | 2008-08-14 | 2011-11-15 | Acceleron Pharma Inc. | Method of increasing red blood cell levels or treating anemia in a patient |
| MY159483A (en) | 2008-11-26 | 2017-01-13 | Amgen Inc | Variants of activin iib receptor polypeptides and uses thereof |
| AU2010204985A1 (en) | 2009-01-13 | 2011-08-04 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
| HUE035240T2 (hu) | 2009-04-27 | 2018-05-02 | Novartis Ag | Készítmények és eljárások az izomerõ növelésére |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| CN107267520A (zh) * | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| CN113171442B (zh) | 2009-08-13 | 2024-11-15 | 阿塞勒隆制药公司 | Gdf捕获物和促红细胞生成素受体激活剂联合应用以增加红细胞水平 |
| MX340451B (es) * | 2009-09-09 | 2016-07-08 | Acceleron Pharma Inc | Antagonistas de actriib y dosificacion y usos de los mismos. |
| JP5836961B2 (ja) | 2009-11-03 | 2015-12-24 | アクセルロン ファーマ， インコーポレイテッド | 脂肪肝疾患を処置するための方法 |
| US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
| US20110268736A1 (en) | 2010-04-30 | 2011-11-03 | Children's Medical Center Corporation | Method for treating congenital myopathy |
| WO2012027065A2 (en) | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
| DK3520805T3 (da) | 2011-10-17 | 2021-04-19 | Acceleron Pharma Inc | Sammensætninger til behandling af myelofibrose |
| US8765385B2 (en) | 2011-10-27 | 2014-07-01 | Ravindra Kumar | Method of detection of neutralizing anti-actriib antibodies |
| US8871209B2 (en) | 2011-11-14 | 2014-10-28 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and or Activin A |
| GR1007832B (el) * | 2011-11-21 | 2013-02-14 | Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, | Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη" |
| US9809636B2 (en) | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
| WO2014066486A2 (en) | 2012-10-24 | 2014-05-01 | Celgene Corporation | Biomarker for use in treating anemia |
| AU2013337677B2 (en) | 2012-11-02 | 2018-06-28 | Celgene Corporation | Activin-ActRII antagonists and uses for treating bone and other disorders |
| SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
| US20140220033A1 (en) | 2013-02-01 | 2014-08-07 | Santa Maria Biotherapeutics, Inc. | Administration of an Anti-Activin-A Compound to a Subject |
| KR20160127148A (ko) | 2014-03-21 | 2016-11-02 | 악셀레론 파마 인코포레이티드 | 액티빈 b 및/또는 gdf11을 억제함으로써 적혈 혈액 세포 수준을 증가시키고 비효율적인 적혈구 생성을 치료하는 방법 |
| EP3131931B1 (en) | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CA2952231A1 (en) | 2014-06-13 | 2015-12-17 | Santa Maria Biotherapeutics, Inc. | Formulated receptor polypeptides and related methods |
| BR122023023170A2 (pt) | 2014-06-13 | 2024-02-20 | Acceleron Pharma Inc. | Uso de um antagonista de actrii no tratamento ou prevenção de úlcera cutânea associada com beta-talassemia |
| US20160075772A1 (en) | 2014-09-12 | 2016-03-17 | Regeneron Pharmaceuticals, Inc. | Treatment of Fibrodysplasia Ossificans Progressiva |
| CN107533040B (zh) | 2014-12-03 | 2022-03-29 | 细胞基因公司 | 激活素-actrii拮抗剂及用于治疗贫血症的用途 |
| MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
| JP7055636B2 (ja) | 2015-04-06 | 2022-04-18 | アクセルロン ファーマ インコーポレイテッド | ＡＬＫ７：ＡｃｔＲＩＩＢヘテロ多量体およびその使用 |
| SMT202100294T1 (it) * | 2015-04-22 | 2021-07-12 | Biogen Ma Inc | Proteine trappola del liganto acriib ibride innovative per il trattamento di patologie da deperimento muscolare |
| CA2996996A1 (en) | 2015-08-31 | 2017-03-09 | National Research Council Of Canada | Tgf-.beta.-receptor ectodomain fusion molecules and uses thereof |
| EP3370754A4 (en) | 2015-11-04 | 2019-10-23 | Acceleron Pharma Inc. | METHOD FOR INCREASING ERYTHROCYTE CONCENTRATION AND TREATMENT OF INEFFICIENT ERYTHROPOIESE |
| WO2017091706A1 (en) | 2015-11-23 | 2017-06-01 | Acceleron Pharma Inc. | Methods for treating eye disorders |
| WO2017192847A1 (en) * | 2016-05-04 | 2017-11-09 | University Of Cincinnati | Female fertility therapies |
| IL301468A (en) | 2016-06-13 | 2023-05-01 | Scholar Rock Inc | Use of myostatin inhibitors and combination therapies |
| KR102761094B1 (ko) * | 2016-10-05 | 2025-02-03 | 악셀레론 파마 인코포레이티드 | 변이체 actriib 단백질 및 이의 용도 |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CN120535607A (zh) * | 2018-01-12 | 2025-08-26 | 科乐斯疗法公司 | 激活素受体iib型变体及其使用方法 |
-
2017
- 2017-06-16 JO JOP/2019/0085A patent/JOP20190085A1/ar unknown
- 2017-10-18 TW TW106135727A patent/TWI826358B/zh active
- 2017-10-19 CN CN201780069411.8A patent/CN109922821A/zh active Pending
- 2017-10-19 SG SG10201913301TA patent/SG10201913301TA/en unknown
- 2017-10-19 IL IL266032A patent/IL266032B2/en unknown
- 2017-10-19 CR CR20190247A patent/CR20190247A/es unknown
- 2017-10-19 MA MA046585A patent/MA46585A/fr unknown
- 2017-10-19 EA EA201990971A patent/EA201990971A1/ru unknown
- 2017-10-19 TN TNP/2019/000119A patent/TN2019000119A1/en unknown
- 2017-10-19 KR KR1020197014056A patent/KR20190071758A/ko not_active Ceased
- 2017-10-19 WO PCT/US2017/057351 patent/WO2018075747A1/en not_active Ceased
- 2017-10-19 CA CA3039066A patent/CA3039066A1/en active Pending
- 2017-10-19 MX MX2019004651A patent/MX2019004651A/es unknown
- 2017-10-19 SG SG11201903450YA patent/SG11201903450YA/en unknown
- 2017-10-19 US US16/343,366 patent/US20190330307A1/en not_active Abandoned
- 2017-10-19 AU AU2017345435A patent/AU2017345435B2/en active Active
- 2017-10-19 PE PE2019000842A patent/PE20190743A1/es unknown
- 2017-10-19 JP JP2019521409A patent/JP2019535675A/ja active Pending
- 2017-10-19 EP EP17861941.7A patent/EP3528833B1/en active Active
-
2019
- 2019-04-17 PH PH12019500853A patent/PH12019500853A1/en unknown
- 2019-04-18 CL CL2019001069A patent/CL2019001069A1/es unknown
- 2019-05-17 ZA ZA2019/03105A patent/ZA201903105B/en unknown
- 2019-05-20 CO CONC2019/0005115A patent/CO2019005115A2/es unknown
-
2021
- 2021-12-07 US US17/544,579 patent/US12187783B2/en active Active
-
2024
- 2024-11-25 US US18/959,069 patent/US20250109183A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| SG11201903450YA (en) | 2019-05-30 |
| JP2019535675A (ja) | 2019-12-12 |
| WO2018075747A1 (en) | 2018-04-26 |
| MA46585A (fr) | 2019-08-28 |
| ZA201903105B (en) | 2023-03-29 |
| JOP20190085A1 (ar) | 2019-04-17 |
| MX2019004651A (es) | 2019-10-09 |
| CR20190247A (es) | 2019-07-29 |
| SG10201913301TA (en) | 2020-03-30 |
| TW201827069A (zh) | 2018-08-01 |
| US20250109183A1 (en) | 2025-04-03 |
| US12187783B2 (en) | 2025-01-07 |
| CA3039066A1 (en) | 2018-04-26 |
| IL266032B2 (en) | 2024-06-01 |
| CN109922821A (zh) | 2019-06-21 |
| AU2017345435B2 (en) | 2021-11-11 |
| IL266032A (en) | 2019-06-30 |
| IL266032B1 (en) | 2024-02-01 |
| CL2019001069A1 (es) | 2019-08-23 |
| US20190330307A1 (en) | 2019-10-31 |
| TN2019000119A1 (en) | 2020-10-05 |
| TWI826358B (zh) | 2023-12-21 |
| EP3528833A1 (en) | 2019-08-28 |
| KR20190071758A (ko) | 2019-06-24 |
| EP3528833A4 (en) | 2020-11-25 |
| CO2019005115A2 (es) | 2019-05-31 |
| EA201990971A1 (ru) | 2019-10-31 |
| PE20190743A1 (es) | 2019-05-27 |
| EP3528833B1 (en) | 2025-12-24 |
| US20220332791A1 (en) | 2022-10-20 |
| AU2017345435A1 (en) | 2019-05-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12019500853A1 (en) | Methods for treating muscle wasting and bone disease using novel hybrid actriib ligand trap proteins | |
| ZA202210065B (en) | Interleukin-21 muteins and methods of treatment | |
| PH12020551317A1 (en) | Anti-cd73 antibodies and methods of use thereof | |
| MX2021006615A (es) | Proteinas de union triespecificas y metodos de uso. | |
| PH12018502400A1 (en) | Anti-tim-3 antibodies and methods of use thereof | |
| PH12018501220A1 (en) | Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof | |
| EP4289484A3 (en) | Anti-ctla-4 antibodies and methods of use thereof | |
| MX2025012685A (es) | Anticuerpos para claudin6 y metodos para tratar el cancer | |
| WO2018226578A8 (en) | Nectin-4 binding proteins and methods of use thereof | |
| EA201892774A1 (ru) | Антитела | |
| EA201890337A1 (ru) | Конструкции антитела к flt3 и cd3 | |
| WO2018170150A3 (en) | Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteins | |
| EP4183806A3 (en) | Glycan-interacting compounds and methods of use | |
| BR112013003823A2 (pt) | conjugados de peptídeo terapêutico-políemro, partículas, composições, e métodos relacionados | |
| WO2016063026A3 (en) | Selective nav protein binders | |
| MX2018011035A (es) | Anticuerpos-anti-mica. | |
| WO2015200883A3 (en) | Semi-synthetic nurse shark vnar libraries for making and using selective binding compounds | |
| EA201991704A2 (ru) | Моноклональные антитела против ингибитора пути тканевого фактора (tfpi) | |
| WO2016149613A3 (en) | Selective mcl-1 binding peptides | |
| MA39342B2 (fr) | Anticorps il -21 | |
| SG10201903142RA (en) | Serpin fusion polypeptides and methods of use thereof | |
| MX377300B (es) | Terapia con células madre en patologías endometriales. | |
| MX2020009550A (es) | Proteinas de union a antigeno antagonistas. | |
| PH12019501108A1 (en) | Anti-gitr anti-binding protein and methods of use thereof | |
| PH12019502449A1 (en) | Anti-jagged1 antigen binding proteins |